Foghorn Therapeutics Provides Update on Phase I Study of FHD-286 in Relapsed and/or Refractory AML and MDS

Foghorn Therapeutics Inc. announced the FDA has placed the Phase I dose escalation study of FHD-286 in relapsed and/or refractory acute myelogenous leukemia and myelodysplastic syndrome on a partial clinical hold.